192 related articles for article (PubMed ID: 32047850)
1. Folate receptor alpha expression associates with improved disease-free survival in triple negative breast cancer patients.
Norton N; Youssef B; Hillman DW; Nassar A; Geiger XJ; Necela BM; Liu H; Ruddy KJ; Polley MC; Ingle JN; Couch FJ; Perez EA; Liu MC; Carter JM; Leon-Ferre RA; Boughey JC; Somers EB; Kalari KR; Visscher DW; Goetz MP; Knutson KL
NPJ Breast Cancer; 2020; 6():4. PubMed ID: 32047850
[TBL] [Abstract][Full Text] [Related]
2. Correlation of folate receptor alpha expression with clinicopathological parameters and outcome in triple negative breast cancer.
Zagorac I; Lončar B; Dmitrović B; Kralik K; Kovačević A
Ann Diagn Pathol; 2020 Oct; 48():151596. PubMed ID: 32829070
[TBL] [Abstract][Full Text] [Related]
3. Anti-Folate Receptor Alpha-Directed Antibody Therapies Restrict the Growth of Triple-negative Breast Cancer.
Cheung A; Opzoomer J; Ilieva KM; Gazinska P; Hoffmann RM; Mirza H; Marlow R; Francesch-Domenech E; Fittall M; Dominguez Rodriguez D; Clifford A; Badder L; Patel N; Mele S; Pellizzari G; Bax HJ; Crescioli S; Petranyi G; Larcombe-Young D; Josephs DH; Canevari S; Figini M; Pinder S; Nestle FO; Gillett C; Spicer JF; Grigoriadis A; Tutt ANJ; Karagiannis SN
Clin Cancer Res; 2018 Oct; 24(20):5098-5111. PubMed ID: 30068707
[No Abstract] [Full Text] [Related]
4. Folate Receptor α-Targeted
Heo GS; Detering L; Luehmann HP; Primeau T; Lee YS; Laforest R; Li S; Stec J; Lim KH; Lockhart AC; Liu Y
Mol Pharm; 2019 Sep; 16(9):3996-4006. PubMed ID: 31369274
[TBL] [Abstract][Full Text] [Related]
5. A phase II study of Mirvetuximab Soravtansine in triple-negative breast cancer.
Yam C; Rauch GM; Rahman T; Karuturi M; Ravenberg E; White J; Clayborn A; McCarthy P; Abouharb S; Lim B; Litton JK; Ramirez DL; Saleem S; Stec J; Symmans WF; Huo L; Damodaran S; Sun R; Moulder SL
Invest New Drugs; 2021 Apr; 39(2):509-515. PubMed ID: 32984932
[TBL] [Abstract][Full Text] [Related]
6. Folate receptor α is associated with poor clinicopathological perspectives in breast carcinoma.
Aboulhagag NAE; Torky RF; Fadel SA
Pathophysiology; 2018 Mar; 25(1):71-76. PubMed ID: 29395794
[TBL] [Abstract][Full Text] [Related]
7. A phase I study of Mirvetuximab Soravtansine and gemcitabine in patients with FRα-positive recurrent ovarian, primary peritoneal, fallopian tube, or endometrial cancer, or triple negative breast cancer.
Cristea MC; Stewart D; Synold T; Ruel N; Mortimer J; Wang E; Jung A; Wilczynski S; Konecny GE; Eng M; Kilpatrick L; Han E; Dellinger T; Hakim A; Lee S; Morgan RJ; Wakabayashi MT; Frankel PH
Gynecol Oncol; 2024 Mar; 182():124-131. PubMed ID: 38262235
[TBL] [Abstract][Full Text] [Related]
8. Folate Receptor Alpha Expression Is Associated With Increased Risk of Recurrence in Triple-negative Breast Cancer.
Ginter PS; McIntire PJ; Cui X; Irshaid L; Liu Y; Chen Z; Shin SJ
Clin Breast Cancer; 2017 Nov; 17(7):544-549. PubMed ID: 28410844
[TBL] [Abstract][Full Text] [Related]
9. Folate receptor-α expression in resectable hepatic colorectal cancer metastases: patterns and significance.
D'Angelica M; Ammori J; Gonen M; Klimstra DS; Low PS; Murphy L; Weiser MR; Paty PB; Fong Y; Dematteo RP; Allen P; Jarnagin WR; Shia J
Mod Pathol; 2011 Sep; 24(9):1221-8. PubMed ID: 21572402
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of survivin and EGFR protein expression in triple-negative breast cancer (TNBC) patients.
Zhang M; Zhang X; Zhao S; Wang Y; Di W; Zhao G; Yang M; Zhang Q
Target Oncol; 2014 Dec; 9(4):349-57. PubMed ID: 24233638
[TBL] [Abstract][Full Text] [Related]
11. Expression status of folate receptor alpha is a predictor of survival in pancreatic ductal adenocarcinoma.
Cai L; Michelakos T; Ferrone CR; Zhang L; Deshpande V; Shen Q; DeLeo A; Yamada T; Zhang G; Ferrone S; Wang X
Oncotarget; 2017 Jun; 8(23):37646-37656. PubMed ID: 28430580
[TBL] [Abstract][Full Text] [Related]
12. Immunohistochemical co-expression status of cytokeratin 5/6, androgen receptor, and p53 as prognostic factors of adjuvant chemotherapy for triple negative breast cancer.
Maeda T; Nakanishi Y; Hirotani Y; Fuchinoue F; Enomoto K; Sakurai K; Amano S; Nemoto N
Med Mol Morphol; 2016 Mar; 49(1):11-21. PubMed ID: 26009308
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of tumor-infiltrating lymphocytes in patients with early-stage triple-negative breast cancers (TNBC) who did not receive adjuvant chemotherapy.
Park JH; Jonas SF; Bataillon G; Criscitiello C; Salgado R; Loi S; Viale G; Lee HJ; Dieci MV; Kim SB; Vincent-Salomon A; Curigliano G; André F; Michiels S
Ann Oncol; 2019 Dec; 30(12):1941-1949. PubMed ID: 31566659
[TBL] [Abstract][Full Text] [Related]
14. Impact of HER2-low status for patients with early-stage breast cancer and non-pCR after neoadjuvant chemotherapy: a National Cancer Database Analysis.
Li H; Plichta JK; Li K; Jin Y; Thomas SM; Ma F; Tang L; Wei Q; He YW; Chen Q; Guo Y; Liu Y; Zhang J; Luo S
Breast Cancer Res Treat; 2024 Feb; 204(1):89-105. PubMed ID: 38066250
[TBL] [Abstract][Full Text] [Related]
15. Expression of CD22 in Triple-Negative Breast Cancer: A Novel Prognostic Biomarker and Potential Target for CAR Therapy.
Zaib T; Cheng K; Liu T; Mei R; Liu Q; Zhou X; He L; Rashid H; Xie Q; Khan H; Xu Y; Sun P; Wu J
Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768478
[TBL] [Abstract][Full Text] [Related]
16. Expression of neuroendocrine markers predicts increased survival in triple-negative breast cancer patients.
Xia C; Shen S; Pang J; Chen L; Yan J; Liang Z; Ren X
Front Endocrinol (Lausanne); 2023; 14():1205631. PubMed ID: 38125789
[TBL] [Abstract][Full Text] [Related]
17. HER3 status by immunohistochemistry is correlated with poor prognosis in hormone receptor-negative breast cancer patients.
Bae SY; La Choi Y; Kim S; Kim M; Kim J; Jung SP; Choi MY; Lee SK; Kil WH; Lee JE; Nam SJ
Breast Cancer Res Treat; 2013 Jun; 139(3):741-50. PubMed ID: 23722313
[TBL] [Abstract][Full Text] [Related]
18. Targeting folate receptor alpha for cancer treatment.
Cheung A; Bax HJ; Josephs DH; Ilieva KM; Pellizzari G; Opzoomer J; Bloomfield J; Fittall M; Grigoriadis A; Figini M; Canevari S; Spicer JF; Tutt AN; Karagiannis SN
Oncotarget; 2016 Aug; 7(32):52553-52574. PubMed ID: 27248175
[TBL] [Abstract][Full Text] [Related]
19. Association of p53 expression with poor prognosis in patients with triple-negative breast invasive ductal carcinoma.
Li JP; Zhang XM; Zhang Z; Zheng LH; Jindal S; Liu YJ
Medicine (Baltimore); 2019 May; 98(18):e15449. PubMed ID: 31045815
[TBL] [Abstract][Full Text] [Related]
20. High expression of folate receptor alpha is associated with poor prognosis in patients with cervical cancer.
Yazaki S; Kojima Y; Yoshida H; Takamizawa S; Kitadai R; Nishikawa T; Shimoi T; Sudo K; Saito A; Okuma HS; Tanioka M; Noguchi E; Uno M; Ishikawa M; Kato T; Fujiwara Y; Ohe Y; Yonemori K
J Gynecol Oncol; 2022 Nov; 33(6):e82. PubMed ID: 36245230
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]